Oncotarget

Meta-Analysis:

MicroRNAs with prognostic significance in osteosarcoma: a systemic review and meta-analysis

Dong Cheng, Xubin Qiu, Ming Zhuang, Chenlei Zhu, Hongjun Zou and Zhiwei Liu _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:81062-81074. https://doi.org/10.18632/oncotarget.19009

Metrics: PDF 1355 views  |   HTML 1728 views  |   ?  


Abstract

Dong Cheng1, Xubin Qiu1, Ming Zhuang1, Chenlei Zhu1, Hongjun Zou1 and Zhiwei Liu1

1Department of Orthopedics, The Third Affiliated Hospital of Soochow University, Changzhou 213003, P.R. China

Correspondence to:

Zhiwei Liu, email: czyylzw@163.com

Keywords: microRNAs, osteosarcoma, prognosis

Received: March 22, 2017     Accepted: June 19, 2017     Published: July 05, 2017

ABSTRACT

Introduction: This study aimed to elucidate the prognostic value of microRNAs (miRNAs) in patients with osteosarcoma.

Materials and Methods: Studies were recruited by searching PubMed, Embase, the Cochrane Library, China National Knowledge Infrastructure, and Wanfang data-bases (final search update conducted January 2017). Eligible studies were identified and the quality was assessed using multiple search strategies.

Results: A total of 55 articles that investigated the correlation between miRNA expression and either patient survival or disease recurrence in osteosarcoma was initially identified. Among these, 30 studies were included in the meta-analysis. The results of our meta-analysis revealed that elevated levels of miR-21, miR-214, miR-29, miR-9 and miR-148a were associated with poor prognosis in osteosarcoma. Additionally, downregulated miR-382, miR26a, miR-126, miR-195 and miR-124 expression indicated poor prognosis in osteosarcoma.

Conclusions: miRNAs may act as independent prognostic factors in patients with osteosarcoma and are useful in stratifying risk.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 19009